ImVitro, a Paris, France-based SaaS platform, raised $2.5 million in a seed round. $2.5 million seed round led by the only VC firm, New York-based LDV Capital, with participation from MMC Ventures, Tiny VC, Fly Ventures, and Compound VC.
With this funding, ImVitro plans to make strategic hires in both its technical and sales teams as it gears up for a prolonged expansion into the U.S. market.
ImVitro founder and CEO Dr. Alexandra Boussommier explained that the company’s SaaS platform combines the power of cell culture and AI to bring automation to the IVF fertility imaging process, thereby saving clinicians’ valuable time, eliminating a number of human errors and delivering reliable predictions to embryologists at scale. And not least to mention, providing patients with an increased and improved layer of transparency to the entire process.
Its Embryoly platform has already benchmarked its performances against 13 embryologists in a retrospective clinical trial and is in use by more than 10 clinics in France and Spain.
Round: Seed Round
Funding Month: December 2022
Lead Investors: LDV Capital
Additional Investors: MMC Ventures, Tiny VC, Fly Ventures, and Compound VC
Company Website: https://im-vitro.com/
Software Category: in vitro fertilization (IVF)
About the Company: Founded in 2019, ImVitro is an early-stage DeepTech startup that offers a SaaS platform that applies AI to In vitro fertilization imaging needs. The startup is applying computer vision and artificial intelligence technologies to the IVF fertility imaging process, introducing an automated mechanism of embryo evaluation that taps into a multi-centric, multi-time-lapse dataset that is equivalent to more than 50 years of embryology expertise. It aims to facilitate in vitro fertilization (IVF) using artificial intelligence to help the increasing number of people with fertility issues.